These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34788414)

  • 21. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for familial hypercholesterolaemia.
    Bender R; Bell DA; Hooper AJ; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR
    Pathology; 2012 Feb; 44(2):122-8. PubMed ID: 22228254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
    Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
    J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Jahn B; Santamaria J; Dieplinger H; Binder CJ; Ebenbichler C; Scholl-Bürgi S; Conrads-Frank A; Rochau U; Kühne F; Stojkov I; Todorovic J; James L; Siebert U
    Atherosclerosis; 2022 Aug; 355():15-29. PubMed ID: 35870306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genetics and screening of familial hypercholesterolaemia.
    Henderson R; O'Kane M; McGilligan V; Watterson S
    J Biomed Sci; 2016 Apr; 23():39. PubMed ID: 27084339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Evaluation of Population-Based
    Manchanda R; Sun L; Patel S; Evans O; Wilschut J; De Freitas Lopes AC; Gaba F; Brentnall A; Duffy S; Cui B; Coelho De Soarez P; Husain Z; Hopper J; Sadique Z; Mukhopadhyay A; Yang L; Berkhof J; Legood R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 30. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Miserez AR; Martin FJ; Spirk D
    Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    Sun L; Brentnall A; Patel S; Buist DSM; Bowles EJA; Evans DGR; Eccles D; Hopper J; Li S; Southey M; Duffy S; Cuzick J; Dos Santos Silva I; Miners A; Sadique Z; Yang L; Legood R; Manchanda R
    JAMA Oncol; 2019 Dec; 5(12):1718-1730. PubMed ID: 31580391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Martin R; Latten M; Hart P; Murray H; Bailie DA; Crockard M; Lamont J; Fitzgerald P; Graham CA
    Atherosclerosis; 2016 Nov; 254():8-13. PubMed ID: 27680772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia.
    Martin AC; Hooper AJ; Norman R; Nguyen LT; Burnett JR; Bell DA; Brett T; Garton-Smith J; Pang J; Nowak KJ; Watts GF
    J Paediatr Child Health; 2022 Feb; 58(2):281-287. PubMed ID: 34387892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
    Nordestgaard BG; Chapman MJ; Humphries SE; Ginsberg HN; Masana L; Descamps OS; Wiklund O; Hegele RA; Raal FJ; Defesche JC; Wiegman A; Santos RD; Watts GF; Parhofer KG; Hovingh GK; Kovanen PT; Boileau C; Averna M; Borén J; Bruckert E; Catapano AL; Kuivenhoven JA; Pajukanta P; Ray K; Stalenhoef AF; Stroes E; Taskinen MR; Tybjærg-Hansen A;
    Eur Heart J; 2013 Dec; 34(45):3478-90a. PubMed ID: 23956253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?
    Page MM; Bell DA; Watts GF
    Clin Genet; 2020 Apr; 97(4):543-555. PubMed ID: 31833051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic analysis of familial hypercholesterolaemia in Western Australia.
    Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM
    Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
    Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
    PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis.
    Zhang L; Bao Y; Riaz M; Tiller J; Liew D; Zhuang X; Amor DJ; Huq A; Petelin L; Nelson M; James PA; Winship I; McNeil JJ; Lacaze P
    Genet Med; 2019 Sep; 21(9):1958-1968. PubMed ID: 30773532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.